Update of early phase clinical trials in cancer immunotherapy

키워드

참고문헌 (104)

1. Anderson AC, "Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immunity regulation", Immunity, 44, pp.989~1004 (2016)
2. Koyama S, "Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immunity checkpoints", Nat Commun, 7, pp.10501~ (2016)
3. Lepletier A, "Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma", Clin Cancer Res, 26, pp.3671~3368 (2020)
4. He W, "CD155T", TIGIT Signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer, 2017, pp.77, 6375~6388
5. Chauvin J-M, "TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients", J Clin Invest, 125, pp.2046~2058 (2015)
6. Bendell JC, "Phase Ia", Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors, 2020, pp.16, ~
7. Rodriguez-Abreu D, "Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab(tira)plus atezolizumab(atezo)versus placebo plus atezo as firstline(1L). treatment in patients with PD-L1-selected NSCLC(CITYSCAPE)", J Clin Oncol, 38(suppl 15) (2020)
8. Ahn MJ, "Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1", PD-L1-refractory NSCLC, 2020, pp.31(suppl 4), S887~
9. Niu J, "Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1", PD-L1-naive NSCLC, 2020, pp.31(suppl 4), S891~S892
10. Ascierto PA, "Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1", PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations, 2017, pp.28(suppl 5), V611~V612
11. Felip E, "Initial results from a phase II study(TACTI-002)in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha(soluble LAG-3 protein). and pembrolizumab", J Clin Oncol, 38(suppl 15) (2020)
12. Hong DS, "Phase I", II study of LAG525 ± spartalizumab(PDR001)in patients(pts)with advanced malignancies, 2018, pp.36(suppl 15), ~
13. Lakhani B, "The anti-LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study", J Immunother Cancer, 6(suppl 1), pp.115~ (2018)
14. Davar D, "A phase 1study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma", J Immunother Cancer, 6(suppl 1), pp.114~ (2018)
15. Villarroel-Espindola F, "Spatially resolved and quantitative analysis of VISTA", PD-1H as a novel immunotherapy target in human non-small cell lung cancer, 2018, pp.24, 1562~1573
16. Deng J, "Hypoxia-induced VISTA promotes the suppressive function of myeloidderived suppressor cells in the tumor microenvironment", Cancer Immunol Res, 7, pp.1019~1090 (2019)
17. Radhakrishnan VS, "Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immunity checkpoints VISTA and PD-1, in patients(pts)with advanced solid tumor and Hodgkin lymphoma", J Immunother Cancer, 6(suppl 1), pp.115~ (2018)
18. Radhakrishnan V, "Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1", Ann Oncol, 30(suppl 5), pp.V475~V532 (2019)
19. Suh WK, "The B7family member B7-H3 preferentially down-regulates T helper type 1-mediated immunity responses", Nat Immunol, 4, pp.899~906 (2003)
20. Lee Y, "Inhibition of the B7-H3 immunity-checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function", Cell Res, 27, pp.1034~1045 (2017)
21. Powderly J, "Interim results of an ongoing phase 1, dose escalation study of MGA271(Fc-optimized humanized anti-B7-H3 monoclonal antibody)in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3", J Immunother Cancer, 3(suppl 2) (2015)
22. Aggarwal C, "A phase 1, open-label, dose escalation study of Enoblituzumab in combination with Pembrolizumab in patients with select solid tumors", J Immunotherapy Cancer, 6(suppl 2), pp.114~ (2018)
23. Yap TA, "Improved progression-free and overall survival (PFS", OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial, 2011, pp.79(suppl 13), ~
24. Rischin D, "Inducible T cell costimulatory (ICOS) receptor agonist, GSK 3359609 (GSK609) alone and in combination with Pembrolizumab (pembro): preliminary results from INDUCE-1expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)", Ann Oncol, 30(suppl 5), pp.V449~V474 (2019)
25. Diab A, "A first-inhuman (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies", Ann Oncol, 27(suppl 6), pp.V359~V378 (2016)
26. Postel-Vinay S, "Abstract CT150: A first-in-human phase I study of the OX40 ago(Pts) with selected advanced solid tumors (ENGAGE-1)", Cancer Res, 80(suppl 16) (2020)
27. Glisson BS, "Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors", Clin Cancer Res, 26, pp.5358~5367 (2020)
28. Curti BD, "OX40 is a potent immunity-stimulating target in late-stage cancer patients", Cancer Res, 73, pp.7189~7198 (2013)
29. Infante JR, "A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors", J Clin Oncol, 34(suppl 15) (2016)
30. Koon H, "First-inhuman phase 1 single-dose study of TRX-518, an antihuman glucocorticoid-induced tumor necrosis factor receptor(GITR)monoclonal antibody in adults with advanced solid tumors", J Clin Oncol, 34(suppl 15) (2016)
31. Zappasodi R, "Rational design of anti-GITR-based combination immunotherapy", Nat Med, 25, pp.759~766 (2019)
32. Papadopoulos KP, "Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors", J Clin Oncol, 37(suppl 15) (2019)
33. Geva R, "Firstin-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors", Cancer, 15, pp.4926~4935 (2020)
34. Heinhuis KM, "Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor-related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors : a phase 1", 2a dose-escalation and cohort-expansion clinical trial, 2020, pp.6, 100~107
35. Tran B, "Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors", J Immunother Cancer, 6, pp.93~ (2018)
36. Balmanoukian A, "Safety and clinical activity of MEDI1873, a novel GITR agonist, in advanced solid tumors", Clin Cancer Res, 26, pp.6196~6203 (2020)
37. Chan IH, "In vitro functional activity of OMP-336B11, a GITRL-Fc fusion protein, on primary human immunity cells", Cancer Res, 78(suppl 13) (2018)
38. Segal NH, "Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody", Clin Cancer Res, 23, pp.1929~1936 (2017)
39. Zhang J, "S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity", Onco-Immunology, 7, pp.e1296996~ (2018)
40. Timmerman J, "Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma", Am J Hematol, 95, pp.510~520 (2020)
41. Massarelli E, "Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies", J Immunother Cancer, 4, pp.82~ (2016)
42. Segal NH, "Phase I study of single-agent Utomilumab(PF-05082566), a 4-1BB", CD137agonist, in patients with advanced cancer, 2018, pp.24, 1816~1823
43. Gopal AK, "First-in-human study of Utomilumab, a 4-1BB", CD137 agonist, in combination with Rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas, 2020, pp.26, 2524~2534
44. Tolcher AW, "Phase Ib study of utomilumab(PF-05082566), a 4-1BB", CD137agonist, in combination with pembrolizumab(MK-3475)in patients with advanced solid tumors, 2017, pp.23, 5349~5357
45. Cohen EEW, "A phase Ib study of utomilumab(PF-05082566)in combination with mogamulizumab in patients with advanced solid tumors", J Immunother Cancer, 7, pp.342~ (2019)
46. Compte M, "A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity", Nat Commun, 9, pp.4809~ (2018)
47. Piha-Paul S, "Phase 1dose escalation study of PRS-343, a HER2", 4-1BB bispecific molecule, in patients with HER2+ malignancies, 2019, pp.8(suppl 1), ~
48. Ansell SM, "Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies", Blood Adv, 4, pp.1917~1926 (2020)
49. Aftimos P, "Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies", Clin Cancer Res, 23, pp.6411~6420 (2017)
50. Bagot M, "ARGX-110 for treatment of CD70-positive advanced cutaneous T-cell lymphoma in a phase 1", 2 Clinical Trial, 2018, pp.132(suppl 1), 1627~
51. Ochsenbein AF, "ARGX-110 targeting CD70, in combination with azacitidine, shows favorable safety profile and promising anti-leukemia activity in newly diagnosed AML patients in an ongoing phase 1", 2 clinical trial, 2018, pp.132(suppl 1), ~
52. Vonderheide RH, "Clinical activity and immunity modulation in cancer patients treated with CP-870893, a novel CD40 agonist monoclonal antibody", J Clin Oncol, 25, pp.876~883 (2007)
53. Ruter J, "Immunity modulation with weekly dosing of an agonist CD40antibody in a phase I study of patients with advanced solid tumors", Cancer Biol Ther, 10, pp.983~993 (2010)
54. Vonderheide RH, "Phase I study of the CD40 agonist antibody CP-870893 combined with carboplatin and paclitaxel in patients with advanced solid tumors", Oncoimmunology, 2, pp.e23033~ (2013)
55. Beatty GL, "A phase I study of an agonist CD40 monoclonal antibody(CP-870893)in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma", Clin Cancer Res, 19, pp.6286~6295 (2013)
56. Nowak AK, "A phase 1b clinical trial of the CD40-activating antibody CP-870893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma", Ann Oncol, 26, pp.2483~2490 (2015)
57. Johnson M, "First in human study with the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors", J Immunother Cancer, 5(suppl 3) (2017)
58. Vitale LA, "Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy", Cancer Immunol Immunother, 68, pp.233~245 (2019)
59. Grilley-Olson J, "SEACD40, a non-fucosylated CD40 agonist : interim results from a phase 1 study in advanced solid tumors", J Clin Oncol, 36(suppl 15) (2018)
60. Johnson P, "Clinical and biological effects of an agonist anti-CD40 antibody : a Cancer Research UK phase I study", Clin Cancer Res, 21, pp.1321~1328 (2015)
61. O’Hara MH, "A phase 1b study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic ductal adenocarcinoma(PDAC)patients", Cancer Res, 79(suppl 13) (2019)
62. Overman MJ, "Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab)alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc)", J Clin Oncol, 36(suppl 15) (2018)
63. Siu LL, "Preliminary phase 1profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors", Cancer Res, 78(suppl 13) (2018)
64. Fong L, "Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer", Cancer Discov, 10, pp.40~53 (2020)
65. Fong L, "Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1", PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC)patients, 2017, pp.35(suppl 15), ~
66. Fong L, "Adenosine receptor blockade with Ciforadenant ± Atezolizumab in advanced metastatic castration resistant prostate cancer (mCRPC)", J Clin Oncol, 38(suppl 6) (2019)
67. Chippori A, "Phase I", II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC, 2018, pp.36(suppl 15), ~
68. Chiappori A, "Phase I", II study of the A2AR antagonist NIR178(PBF-509)combined with the anti-PD-1 monoclonal antibody spartalizumab in patients with advanced NSCLC, 2018, pp.103(suppl 1), e13~e20
69. Bendell J, "Evidence of immunity activation in the first-in-human phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors", Cancer Res, 79(suppl 13) (2019)
70. Lim EA, "A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635both as monotherapy and in combination in patients with advanced solid malignancies: results from prostate cancer patients", J Clin Oncol, 38(suppl 15) (2020)
71. Powderly JD, "AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts)with advanced tumors: preliminary results from ongoing phase I studies", J Clin Oncol, 37(suppl 15) (2019)
72. Jha GG, "A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC)", J Clin Oncol, 35(suppl 15) (2019)
73. Bahary N, "Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine", nab-paclitaxel for the treatment of patients with metastatic pancreas cancer, 2018, pp.36(suppl 15), ~
74. Zakharia Y, "Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma", J Clin Oncol, 36(suppl 15) (2018)
75. Long GV, "Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma(ECHO-301", KEYNOTE-252) : a phase 3, randomised, double-blind study, 2019, pp.20, 1083~1097
76. Cassier PA, "CSF1R inhibition with emactuzumab in locally advanced diffusetype tenosynovial giant cell tumours of the soft tissue : a dose-escalation and dose-expansion phase 1 study", Lancet Oncol, 16, pp.949~956 (2015)
77. Gomez-Roca CA, "Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced", metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages, 2019, pp.30, 1381~1392
78. Calvo A, "Phase Ib", II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors, 2018, pp.36(suppl 15), ~
79. Advani R, "CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin’s lymphoma", N Engl J Med, 379, pp.1711~1721 (2018)
80. Sallmann DA, "The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results", J Clin Oncol, 37(suppl 15) (2019)
81. Sikic BI, "First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers", J Clin Oncol, 37, pp.946~953 (2019)
82. Abrisqueta P, "Anti-CD47 antibody, CC-90002, in combination with Rituximab in subjects with relapsed and", or refractory non-Hodgkin lymphoma (R, Blood, pp.2019, 134(suppl 1)[DOI]
83. Kim TM, "A Phase 1study of ALX148, a CD47 blocker, in combination with Rituximab in patients with non-Hodgkin lymphoma", Blood, 134(suppl 1) (2019)
84. Chow LQM, "A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy", J Clin Oncol, 38(suppl 15) (2020)
85. Nywening TM, "Targeting tumour-associated macrophages with CCR2inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer, a single-centre, open-label, dose-finding, nonrandomised, phase 1b trial", Lancet Oncol, 17, pp.651~662 (2016)
86. Noel M, "Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel", gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma, 2017, pp.28(suppl 5), V209~V268
87. Pienta KJ, "Phase 2study of carlumab(CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2(CCL2), in metastatic castration-resistant prostate cancer", Invest New Drugs, 31, pp.760~768 (2013)
88. Kim YH, "Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma(MAVORIC) : an international, open-label, randomised, controlled phase 3 trial", Lancet Oncol, 19, pp.1192~1204 (2018)
89. Doi T, "A phase I study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors", Clin Cancer Res, 25, pp.6614~6622 (2019)
90. Zamarin D, "Mogamulizumab in combination with durvalumab or tremelimumab in patients with advanced solid tumors : a phase I study", Clin Cancer Res, 26, pp.4531~4541 (2020)
91. Schott AF, "Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2-negative metastatic breast cancer", Clin Cancer Res, 23, pp.5358~5365 (2017)
92. Salgia R, "A randomized phase II study of LY2510924 and carboplatin", etoposide versus carboplatin, Lung Cancer, pp.2017, 105[DOI]
93. Hainsworth JD, "A randomized, open-label phase 2 study of the CXCR4inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma(RCC)", Target Oncol, 11, pp.643~653 (2016)
94. O’Hara MH, "Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with Durvalumab in advanced refractory solid tumors", J Pancreat cancer, 6, pp.21~31 (2020)
95. Pernas S, "Balixafortide plus eribulin in HER2-negative metastatic breast cancer : a phase 1, single-arm, dose-escalation trial", Lancet Oncol, 19, pp.812~824 (2018)
96. Kaufman PA, "Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial", J Clin Oncol, 37(suppl 15) (2019)
97. Benson DM Jr, "A phase 1 trial of the anti-KIR antibody IPH2101in patients with relapsed", refractory multiple myeloma, 2012, pp.120, 4324~4333
98. Vey N, "A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission", Blood, 120, pp.4317~4323 (2012)
99. Vey N, "A phase 1dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM)or solid malignancies (SOL)", J Clin Oncol, 33(suppl 15) (2015)
100. Leidner R, "Preliminary efficacy from a phase 1", 2 study of the natural killer cell-targeted antibody, lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck, 2016, pp.4, 91~
101. Bagot M, "IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma : an international, first-in-human, open-label, phase 1 trial", Lancet Oncol, 20, pp.160~170 (2019)
102. Cohen RB, "Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors", J Clin Oncol, 38(suppl 15) (2020)
103. Harrington KJ, "Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas", Ann Oncol, 29(suppl 8), pp.712~ (2018)
104. Meric-Bernstam F, "Phase ib study of miw815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced", metastatic solid tumors or lymphomas, 2019, pp.37(suppl 15), ~

관련 논문AI추천